Floatz logo

SUMOYLATION INHIBITOR TAK-981

Neoplasms

TakedaSmall moleculePhase 1/2Active
D
29/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
17/ 100
Competitive Position
65/ 100

Competitive context

927 Active assets in the Neoplasms cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Inno-206
The First Affiliated Hospital of Soochow University
Phase 2/3BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

SUMOYLATION INHIBITOR TAK-981 is also rated in:

Advanced or Metastatic Solid TumorsDormant
D
Indicative ·
30 / 100
View asset →
plasma cell myelomaDormant
D
Indicative ·
28 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
D
Indicative ·
28 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →